Summit Trail Advisors’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
Other funds holding NVS
Summit Trail Advisors's NVS Position: Q1 2026 in Review
Summit Trail Advisors increased its Novartis (NVS) stake by 436% in Q1 2026, buying an estimated $2.6M and bringing the position to 20,845 shares worth $3.18M. The position accounts for 0.05% of the portfolio, ranked #289.
Summit Trail Advisors first reported a position in NVS in Q4 2017 and has held it in 18 quarters since. 1,591 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Summit Trail Advisors held 20,845 shares of Novartis worth $3.18M as of Q1 2026.
- Summit Trail Advisors bought 16,957 Novartis shares in Q1 2026, an estimated $2.6M.
- Novartis made up 0.05% of Summit Trail Advisors's portfolio in Q1 2026, its #289 holding.
- Summit Trail Advisors first reported a position in Novartis in Q4 2017 and has held it in 18 quarters since.
- 1,591 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Summit Trail Advisors's 13F filing for Q1 2026, filed 12 May 2026.